Research programme : cancer therapeutics - Boehringer Ingelheim/Sarah Cannon Research Institute

Drug Profile

Research programme : cancer therapeutics - Boehringer Ingelheim/Sarah Cannon Research Institute

Alternative Names: BI 754091; BI 754111

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Sarah Cannon Research Institute
  • Class Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 31 Oct 2016 Boehringer Ingelheim plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA and Canada (Parenteral) (NCT02952248)
  • 29 Sep 2016 Early research in Cancer in Germany and USA (Parenteral)
  • 29 Sep 2016 Boehringer Ingelheim and Sarah Cannon Research Institute enter into a collaboration agreement to develop BI 754091 and BI 754111 in USA and Germany for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top